Search Results - "Serrano‐Alonso, M."

Reduction in mortality associated with secondary cytomegalovirus prophylaxis after solid organ transplantation by Serrano‐Alonso, M., Guillen‐Grima, F., Martin‐Moreno, P., Rabago, G., Manrique, J., Garcia‐del‐Barrio, M., Reina, G., Torre‐Cisneros, J., Fernandez‐Alonso, M., Herrero, J.I.

“…Background Cytomegalovirus (CMV) is the most important viral pathogen in solid organ transplant (SOT) recipients. The role of secondary CMV prophylaxis in this…”
Get full text

6ER-034 Use of closed system transfer devices with investigational drug products by Valdeolmillos, L, Garcia Pastor, C, Serrano Alonso, M, Lacasa Arregui, C, Molíns Castiella, E

“…Background and ImportanceInvestigational drug products (IDP) should be treated as hazardous drugs (HD) as it is not frequent to have hazard studies available…”
Get full text

4CPS-084 Anthracycline dosage in paediatric obese patients by Fernandez Garcia, B, Fraile Rodriguez, C, Abasolo Tamayo, X, Herrero Corell, I, Serrano Alonso, M, García-Del-Barrio, MÁ

“…Background and importanceIn 2016, the World Health Organization estimated that 41 million children aged <5 years were overweight. Clinicians are increasingly…”
Get full text

Papel de los IPH-HIF para mejorar la adherencia y la seguridad en el tratamiento de la anemia de la enfermedad renal crónica by Lorenzo Ferris, I., Serrano Alonso, M.

Get full text

4CPS-100 Anthracycline dosing in obese adult patients: a systematic review by Tapia, B, Casas, A, Torroba, B, Fraile, C, Gutierrez, A, Fernandez, B, Serrano-Alonso, M, García Del Barrio, MA

“…Background and importanceChemotherapy dosing for obese patients (body mass index (BMI) ≥30 kg/m2) remains undefined. Most recent publications discourage…”
Get full text

Role of HIF-PHD inhibitor in improving adherence and safety in the treatment of anemia in chronic kidney disease by Lorenzo Ferris, I, Serrano Alonso, M

Get more information